Christos Richards Acquires Shares in Codexis, Inc.

Christos Richards made a significant move by purchasing 66,350 shares of Codexis, Inc. (CDXS) on June 17, 2026. This insider transaction adds to the interest in Codexis, which trades on the NasdaqGS at around $2.57 per share.

What Changed in Christos Richards's Codexis Position

Richards's recent purchase of 66,350 shares represents a notable insider transaction, although specific details about the transaction value weren't disclosed. This acquisition is not part of a pre-planned trading program, indicating a direct investment decision.

Other Institutional Activity in Codexis

Several institutional investors have also been active in Codexis. Aberdeen Group PLC increased its holdings by 713,870 shares, bringing its total to 8,680,368 shares valued at approximately $14.1 million. Meanwhile, BlackRock, Inc. reduced its stake by 366,967 shares, ending with 7,028,773 shares worth about $11.5 million. Millennium Management LLC significantly boosted its position by 862,938 shares, now holding 3,998,130 shares valued at around $6.5 million.

Codexis Stock Snapshot

Shares of Codexis, Inc. (NasdaqGS:CDXS) are currently trading near $2.57. The company has a market capitalization of roughly $233.6 million and a beta of 2.478, indicating higher volatility compared to the market. The stock's 52-week range is between $0.96 and $3.87, with moving averages of $2.569 (50-day) and $2.0225 (200-day). Codexis maintains a strong current ratio of 5.364, although it has a high debt-to-equity ratio of 168.624.

Recent Earnings

Codexis reported revenue of $78.1 million with a modest growth rate of 1.021. However, the company is not currently profitable, with a negative net margin of -40.965% and a return on equity of -68.897%. The next earnings report is expected on August 12, 2026.

Insider Buying and Selling at Codexis, Inc.

On June 17, 2026, several insiders, including Christos Richards, Stewart Parker, David Smith, Rahul Singhvi, Esther Martinborough, and Stephen George Dilly, each acquired 66,350 shares of Codexis. These transactions were not planned under Rule 10b5-1 plans.

Analysts Set New Price Targets

Analyst firms such as Cantor Fitzgerald and Piper Sandler have reiterated their 'buy' ratings for Codexis, with price targets of $11 and $10, respectively. The consensus among analysts is a 'buy' recommendation, with a mean price target of $6.58, based on six opinions.

About Codexis

Codexis, Inc. is a biotechnology company based in Redwood City, California. It develops innovative enzyme solutions for the manufacturing of therapeutics using its proprietary CodeEvolver technology platform. The company works globally, with partnerships and licensing agreements with firms like Aldevron LLC and Pfizer Inc. Led by CEO Dr. Alison Moore, Codexis employs 146 people and focuses on advancing enzyme technologies for RNAi therapeutics.

Bottom Line

Christos Richards's recent purchase of Codexis shares adds to the ongoing interest in the company, which is a player in the biotechnology sector. While the stock's performance shows volatility, it remains a focus for analysts who largely recommend it as a 'buy'. Investors should note that insider transactions like Richards's are reported after the fact and may not reflect the current position.